This study aims to assess the results of kidney retransplantations and the survival of second kidney allografts performed in our center. Methodology: of 550 kidney transplantations performed since July 2001, 26 were second kidney transplants. Many recipients were sensitized. All patients were treated with the same immunosuppressive regimen. Results: grafts were functionally effective in all patients with kidney retransplantations one month after the transplant. Graft survival was 100% after one year (17/17) and after five years (1/1). Graft survival was similar for second and primary kidney transplants performed during the same period of time. There were three cases of acute rejection, but all of these cases responded to the anti-rejection treatment. Conclusions: the rate of acute rejection was similar for both second and primary transplantations in our hospital, and the second graft outcome demonstrated effectiveness 12 months after transplantation.
Introduction
Since immunosuppressive drugs such as CsA, FK 506, or MMF were introduced, the short-term graft survival rate of kidney transplant increased from 10 to 20%, but the rate of chronic rejection remained high [1] . About 5 to 24% of graft dysfunction occurred within five years post-transplant, and 50 to 80% of rejection patients had to return to dialysis [2] . Graft failure has been one of the most common causes of end-stage renal disease, accounting for 25% of 30% of those on the waiting list [3] .
A successful kidney transplant offers enhanced quality and duration of life and is more effective in terms of medical outcome and patient satisfaction relative to longterm dialysis [4] . However, retransplant recipients have a higher risk of immunity reactions relative to those receiving their first grafts [5] [6] [7] . The success of retransplantation has improved significantly due to pre-transplant screening and post-transplant treatment [5] . Recent reports have indicated that the success rate of kidney retransplantations relative to first kidney transplants is nearly identical one year after the transplant. Therefore, the evaluation of the outcome as well as an enhanced understanding of the characteristics of this group of patients is necessary for the optimal treatment of chronic renal failure.
Of 550 cases performed at Hue Central Hospital since 2001, 26 cases were retransplanted. We initiated a second kidney transplant from 2012; this number has increasing every year. As we anticipated, the retransplant rate has increased rapidly. There were 10 patients with immunological risk (PRA>25%), including two cases with PRA of greater than 80%. This article seeks to evaluate the outcome of immunosuppressive therapy on retransplant patients and the renal function of patients at one month and one year post-transplantation. Crossmatches were performed through complementdependent lymphocytotoxicity (CDC).
Methods

Of
Living donors' details, such as age, gender, and serum creatinin were collected. Recipients' features such as gender, antibodies concentration, HLA mismatches, crossmatches, delay graft function, acute rejection episodes, creatinine intervals at one month, three months, and 12 months post-transplantation, characteristics of the first kidney transplant (graft survival time, interval between two transplants, cause of first graft loss and information on first immunosuppression regimen).
Return to dialysis or death with graft functions was referred to as graft loss. Acute rejections were defined by a combination of clinical criteria and the renal biopsy. Delayed graft functions were defined by requiring at least one dialysis session in the first seven days post-transplantation.
Immunosuppressive regimen
Despite the abundance of immunosuppressive drugs, all patients were treated with quadruple therapy consisting of induction therapy by antithymocyte globulin (ATG) horses or rabbits or monoclonal antibody rather than standard maintenance therapy. The dose of ATG rabbits and horses was 1-1.25 mg/kg/day for seven patients as opposed to 10 patients, respectively. Monoclonal antibody (Basiliximab) was used as the induction regimen for nine patients. Maintenance therapy with cyclosporin (two cases) or FK506 (24 cases) combined with MMF 2 g/day were used along with intravenous corticosteroid, followed by oral administration. The CsA dose was initiated at 7-8 mm/ kg/day in two divided doses and adjusted by trough level to 150-200 ng/ml. Tarcrolimus dose was 0.1-0.15 mg/kg/ day in two divided doses and adjusted by trough level 8-10 ng/ml. Prednisolone was administered at the rate of 0.4 mg/kg/day followed by 0.3 mg/kg/day and then 5 mg/day after three months. Acute rejections were treated with bolus methylprednisolon 500 mg/day x 3 days. ATG was used for treatment of steroid-resistant rejection. For acute mediated antibody, the plasmapheresis was indicated as ± IVIG [8, 9] . There were some immunologically high-risk cases that required highly HLA-matched proportions and more extensive immunosuppression regimens. Of two cases with PRA≥80% and one with acute mediated antibody required plasmapheresis, one had been desensitized pre-transplant with five plasmapheresis sessions pre-transplant.
Results
Number of patients each year
Year 2012 2013 2014 2015 2016 2017 3/2018 Cases 1 0 3 3 7 9 3
Characteristics of donors
HLA antibodies
HLA
Crossmatch
100% of retransplant cases were negative. There were seven cases who had their first transplant at Hue Central Hospital and 16 in China or at other centers.
Timing of first graft survival
Serohepatitis
All patients in this group had been infected and had viral load below detectable levels before transplantation, with anti-HCV positive and HBsAg positive were nine and patients, respectively. All patients with hepatitis virus were placed on low-dose immunosuppression therapy if they had minimal antibodies levels and high HLA matches. The number of kidney retransplants which experienced normal functioning at one month, three months, twelve months, three years, and five years post-transplant were 26, 25, 17, 4, and 1, respectively. 
Acute rejection
There were three cases of acute rejection, which required three to five dialysis sessions; one case with acute mediated antibody needed plasmapheresis. Two cases were treated with bolus solumedrol and ATG. All three cases responded positively to treatment, and kidney function returned to normal before discharge.
Dicussion
We initiated the second kidney transplant starting in March 2012. This number has increased each year because the patients who had previously been transplanted went up and because of immune tests such as the specific HLA antibody Luminex, the experience of the pathology of kidney transplant biopsies, immunosuppressive drugs such as ATG, IVIG... which are fully on the market, the use of plasmapheresis, and knowledge and experience of anti-rejection treatment with high immunologically high-risk recipients [8, 9] .
The disadvantage of this article was that the number of patients remained minimal and the follow-up was relatively short. There was merely one five-year patient. Data analysis performed for 50,291 recipients from deceased brain donors was reported by UNOS from 1991 to 1997; Cecka demonstrated that the rate of patient survival five years post-transplant was 82% and that the graft function rate was 63% [1] ; the research of Stephani's, et al. perceived the rate of second graft survial as only 2% lower than that among living donors or deceased brain donors. In contrast, in one study, Moss, et al. demonstrated that the short-term outcome of kidney retransplantation relative to first kidney transplantation was the same [4] . In our study, kidney retransplant function was successful in 100% of cases when evaluated at one month, three months, and 12 months. There were three cases that involved delayed renal function, but kidney function then returned to normal. Therefore, recipients from living donors, as well as new immunosuppressive agents, have been proven to produce effective results in short-term renal function. Particularly, graft survival rates interval at one year were not different between first transplants and retransplantations in this group.
Acute rejection is a formidable complication in kidney retransplant patients due to the immunological risk involved [2] . Among these 26 retransplant cases, in three cases, acute rejection accounted for 11.54%, equivalent to approximately 10% of transplants in 550 patients at Hue Central Hospital.
The improvement of graft survival reflects the effect of immunosuppressive drugs and the effective control of crossreactions between donors and recipients [3] . Additionally, it would be fruitful to minimise cold ischemia time in renal transplantations from living donors and precisely evaluate
